Anadys Cleared to Start HepC Trial

Luke Timmerman7/30/09

San Diego-based Anadys Pharmaceuticals (NASDAQ: ANDS) said today it has gotten the green light from the FDA to start a mid-stage clinical trial of its experimental hepatitis C drug, ANA598, in combination with the standard treatments, pegylated inferferon alpha and ribavirin. About 90 patients are expected to enroll, with the first joining the study within weeks, the company said. Anadys, which hopes this drug candidate will alter the standard of care for hepatitis C, expects to receive the first results from this study as soon as the end of the year.

Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.